Form 4: Stoke Therapeutics CMO Sells Shares Under 10b5-1 Plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 5,343 shares of common stock for a weighted average price of $23.6414 per share.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported the sale of 5,343 shares of common stock.
• The transaction occurred on October 1, 2025, at a weighted average price of $23.6414 per share.
• The shares were sold in multiple transactions with prices ranging from $23.40 to $24.08 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ticho on December 11, 2024.
• Following the reported transaction, Mr. Ticho beneficially owns 13,126 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was for personal financial planning rather than a reaction to new company-specific information.

Positives

• NA

Negatives

• The Chief Medical Officer sold 5,343 shares of common stock, which could be perceived negatively by some investors, despite being a pre-scheduled transaction.

Risks

• Insider selling, even when pre-planned, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to short-term negative sentiment or share price pressure.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitor activities within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders may note the insider selling activity, which could lead to minor shifts in investor sentiment, although the pre-planned nature of the sale mitigates significant concern.

Key Dates

Recommendation

The sale by the Chief Medical Officer was conducted under a pre-established Rule 10b5-1 trading plan, adopted well in advance of the transaction date. This suggests the sale is for personal financial management rather than a reflection of new, adverse company-specific information. Therefore, this single transaction does not provide sufficient new fundamental data to warrant a change in investment recommendation, and a 'hold' stance is maintained.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Barry Ticho, Stock Sale, Chief Medical Officer, 10b5-1 Plan